Merck's combination of a wide lineup of high-margin drugs and a pipeline of new drugs should ensure strong returns on invested capital over the long term. Further, following the divestment of the ...

MRK provided 2025 adjusted EPS guidance of $8.88 to $9.03, while the giant drugmaker expects sales of $64.1 billion to $65.6 ...

Medicare and Cigna don't cover this medication anymore. Her bills are rent $62 ...

Biden's HHS announced the first batch of negotiated Medicare drug prices in August after negotiating them for months. Those 10 lower prices – which ranged from a price cut of 79% for Type 2 diabetes ...

This is the new norm within the world of medicine, and Merck navigates it nicely even if not explosively. Better still, with the stock now down 25% from June's peak, newcomers will be stepping in at a ...